Arena Pharmaceuticals

We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs. Our internally discovered drug for chronic weight management, BELVIQ ® (lorcaserin HCl), was approved by the FDA for marketing in the United States to adults who are overweight with a comorbidity or obese, and was made available to patients by our collaborator, Eisai, by prescription in June 2013. In February 2015, BELVIQ was also approved for weight management in South Korea and will be marketed by our collaborator, Ildong.
San Diego, US
228 (est)-29%

Arena Pharmaceuticals Locations

San Diego, US
Zofingen, CH

Arena Pharmaceuticals Metrics

Arena Pharmaceuticals Summary

Founding Date


Market capitalization

$382 M

Closing share price


Arena Pharmaceuticals Market Value History

Arena Pharmaceuticals News

Arena Pharmaceuticals Company Life